Developing single molecule methods for measuring the pathway proteins ERK, AKT, cyclin d and p70s6k in localized colon cancer in relation to mutation status

Dorte Aa. Olsen^{1, 3, 4*}, Caroline EB. Thomsen^{2, 3, 4}, Rikke F. Andersen^{1, 3, 4}, Jonna S. Madsen^{1, 3, 4}, Anders Jakobsen^{2, 3, 4} and Ivan Brandslund^{1, 3, 4}

¹ Department of Biochemistry and Immunology, Vejle Hospital, Vejle, Denmark.

² Department of Oncology, Vejle Hospital, Vejle, Denmark.

³ Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

⁴ Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark

* Department of Biochemistry and Immunology

Vejle Hospital

Beriderbakken 4

DK – 7100 Vejle

Phone: +45 79406633

E-mail: dorte.aalund.olsen@rsyd.dk

Short title: Pathway proteins in colon cancer.

Abstract

Background: The aim of this study was to quantify the intracellular pathway proteins ERK, AKT, cyclin d and p70s6k in localized colon cancer tissue to investigate the possible prognostic values and the ability to be used as screening markers for upstream mutations. Methods: Colon cancer tissue and autologous reference tissue were collected from 176 patients who underwent surgery for colon cancer. Assays for quantifying ERK, AKT, cyclin d and p70s6k proteins were developed using single molecule array (Simoa). KRAS/BRAF/PIK3CA mutation status was determined using droplet digital PCR. Results: Patients with BRAF mutations had decreased concentrations of ERK ($p=0.0002$), AKT ($p=0.00004$) and cyclin d ($p=0.001$) while no significant differences were found between patients with KRAS mutations and Wild type (Wt) patients. None of the investigated protein concentrations were associated with disease free survival or overall survival, if including all patients. However, when stratifying according to mutation status, significant correlations to overall survival were seen for patients with BRAF mutations and AKT ($p=0.003$) or ERK ($p=0.046$) and for patients with KRAS mutations and p70s6k ($p=0.04$). Furthermore, the combination of genetic mutations, stage 2 disease, and all of the investigated pathway proteins showed significant correlations to overall survival. Conclusions: There is a strong correlation between pathway protein concentrations and mutational BRAF status. Overall survival in colon cancer patients depend both on gene mutation status and pathway protein concentrations. As significant correlations were found between BRAF mutations and ERK, AKT and cyclin d, concentration measurements of these pathway proteins might be useful as screening for upstream mutations.

Abbreviations

Simoa, Single molecule array; SβG, Streptavidin-β-galactosidase; RGP, resorufin-β-D-galactopyranoside; AEB, average number of enzyme per bead.

48

49 **Keywords**

50 Single molecule array; Simoa; colon cancer; colorectal cancer; prognosis; mutations; AKT; ERK;
51 cyclin d, p70s6k

52

Introduction

The intracellular signaling network of the epidermal growth factor receptor (EGFr) consists of two key signal pathways. The mitogen-activated protein kinase (MAPK) also termed RAS/RAF/MEK/ERK and the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) pathways. They interact in a complex coordinated manner to regulate all stimulated cellular processes and have been described in detail [1;2]. Both ERK and AKT activate more than 100 downstream proteins from the cytosol to the nucleus, including transcription factors, protein kinases, phosphatases and cytoskeletal elements. Thus, they are involved in a wide variety of nuclear and cytosolic processes including cell differentiation, proliferation and oncogenic transformation [3-5]. One important substrate downstream of AKT is mammalian target of rapamycin (mTOR), which promotes protein translation and cell growth through the activation of p70 ribosomal protein S6 kinase (p70s6k) and the eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) [6]. Upon activation synthesis of cyclin d increases, leading to protein synthesis, cell growth and cell cycle progression. A schematic overview of the pathways is illustrated in figure 1.

Fig 1. Simplified graphic illustration of the EGFr pathways RAS/RAF/MEK/ERK and PI3K/AKT.

Activation and dysregulation of intracellular signaling pathways plays a critical role in cancer. A frequent alteration in signaling in colorectal cancer is in the RAS and RAF proteins which result in the proteins being constitutively active and stimulating the ERK signaling pathway even though no signal is present. The occurrence of KRAS and BRAF mutations in colorectal cancers has been found to be approximately 40% and 10-25%, respectively [7-9]. Also dysregulation in the PI3K/AKT pathway due to activating mutations in PI3K (PIK3CA) has been identified in colorectal

cancer [10-12] and PIK3CA mutations have been found to commonly coexist with KRAS or BRAF mutations [11].

The use of inhibitors against growth factor receptors and tyrosine kinase activators has become standard anti- cancer therapy during the last 10 to 15 years. Some of these monoclonal antibodies used in the treatment are Cetuximab as a blocker to EGFr in colorectal cancer and the Trastuzumab HER2 receptor blocker in breast cancer. Mutations in the receptor proteins or in the pathway proteins result in resistance to treatment using these monoclonal antibodies. It is therefore important to detect such mutations at an early phase before treating the patients as it can be predicted whether the treatment will be without effect and thus the patients will only experience side effects of the treatment.

Usually known mutations are diagnosed using PCR or sequencing which are laborious, time consuming, expensive and causes a delay of several days for reporting. In the future, the number of mutations in the pathway proteins will increase and hence will the expense for sequencing or detecting mutations by PCR. Alternative methodology to detect activation of the intracellular pathway proteins could gain importance especially if such methods would be both faster and considerable cheaper.

We therefore aimed to see whether quantification of pathway proteins in colon cancer tissue might reflect upstream mutations and to detect whether changes in concentrations might be correlated to effect of treatment or clinical outcome. We developed quantitative protein assays for measuring phosphorylated ERK (pERK) as a marker of MAPK pathway activation, phosphorylated AKT (pAKT) for PI13K/AKT pathway activation and phosphorylated p70s6k (pp70s6k) for mTOR activation. Also the total protein levels of ERK (tERK), AKT (tAKT), and cyclin d were measured.

99 **Materials and methods**

100 **Patients**

101 A total of 176 patients who underwent surgery for colon cancer at Vejle Hospital during 2010-13
102 were included in the study. Patients with TNM stage 1 (n=8), stage 2 (n=96), and stage 3 (n=68).
103 Four patients had no clinical data available. The study was approved by the Ethics Committee for
104 Southern Denmark (S-20140178).

106 **Samples and controls**

107 Colon cancer tissue was dissected together with autologous reference tissue by an experienced
108 pathologist. The tissue was stored in RNAlater (Qiagen, Hilden, Germany) at -20°C until use.
109 Colon cancer tissue and autologous reference tissue were homogenized in lysis buffer (50mM Tris-
110 HCL, 150 mM NaCl, pH 7.5, 1% triton X-100) including protease and phosphatase inhibitor
111 cocktail 10µl/ml lysis buffer using the dispomix system (Xiril, Hombrechtikon, Switzerland). The
112 samples were afterwards centrifuged at 16.000 g at 4°C for 15 minutes and the supernatant were
113 recovered, aliquoted and stored at -80°C until use. The total protein concentration was measured
114 using the BCA protein assay reagent (Pierce, Rockford, IL, USA). The tissue lysate samples were
115 diluted in lysis buffer to a final concentration of 1 mg/ml and afterwards diluted further in the
116 specific assay reagent. Matched colon cancer tissue and autologous reference tissue samples were
117 analyzed in the same run. Two controls were prepared using reference colon tissue treated equal to
118 the samples. The controls were included in each run and used to determine intra-assay and total
119 coefficient of variation (CV%).

121 **Single molecule array (Simoa)**

The development of quantitative methods and the measurement of the pathway proteins was performed on the automated Simoa HD-1 Analyzer platform (Quanterix©, Lexington, MA, USA). This instrument uses the same reagents as conventional ELISA but uses femtoliter-sized reaction chambers approximately 2 billion times smaller than conventional ELISA. This will result in a rapid buildup of fluorescence if a labeled protein is present which make it possible to detect single molecules. The instrument has previously been described in detail [13].

Reagents

Capture antibodies tAKT and pAKT (DYC887B), tERK and pERK (DYC1230C), pp70s6k (DYC896) (R&D Systems, Minneapolis, MN, USA) and cyclin d (ab218793, Abcam, Cambridge, UK) were covalently attached by standard carbodiimide coupling chemistry to carboxylated paramagnetic beads (Quanterix). The biotinylated detector antibodies and the calibrators were tAKT (DYC1775), pAKT (DYC887B), tERK (DYC1230C), pERK (DYC1018B) (R&D Systems), pp70s6k (DYC896) and cyclin d (ab218793) (abcam). Streptavidin- β -galactosidase (S β G), enzyme substrate resorufin- β -D-galactopyranoside (RGP) and all consumables including wash buffers, cuvettes, disposable tips, and discs were from Quanterix.

Simoa protocol

The six analyses were developed as single-plex assays using a Simoa 2-step assay for tAKT and pAKT and a 3-step assay for tERK, pERK, pp70s6k and cyclin d. Before running the following reagents are prepared; capture beads (1/3) are mixed with helper beads (2/3) in bead diluent buffer (Quanterix) and diluted to a final concentration of 2.0×10^7 beads/ml. The biotinylated detector antibodies are diluted in sample/detector diluent (Quanterix) to final concentrations of 0.2 mg/L for tAKT and pAKT, 0.1 mg/L for tERK, pERK, pp70s6k and cyclin d.

146 The SβG is diluted in SβG diluent (Quanterix) to 150 pM. After loading the prepared reagents and
 147 consumables, the calibrators are prepared in diluent A (Quanterix). The samples and controls are
 148 diluted 30-fold in diluent A and loaded onto the instrument in a 96-well microtiter plate. The
 149 calibrators and the controls are run in duplicates and the samples are single determinations. The
 150 following steps are performed by the instrument. For the 2-step assay, 25 µl of capture bead is
 151 pipetted into a cuvette together with 100 µl of sample, control or calibrator and 50 µl of biotinylated
 152 detection antibody. An incubation step is performed for 30 minutes and the beads are then
 153 magnetically separated and washed. For the 3-step assay, 25 µl of capture bead is pipetted into a
 154 cuvette together with 100 µl of sample, control or calibrator and incubated for 40 minutes. The
 155 beads are then washed and 100 µl of detection antibody is added and an incubation step is
 156 performed for 5 minutes followed by washing the beads. The following steps are identical for both
 157 the 2-step and 3-step assays. 100 µl of SβG is added to the cuvette by the instrument and an
 158 incubation step is performed for 5 minutes. The beads are then separated magnetically and washed
 159 following the addition of RGP substrate. The bead substrate mixture is then loaded on to the Simoa
 160 disc containing an array of 216,000 micro-wells and sealed with oil. If protein has been captured
 161 and labeled, the SβG hydrolyze the RGP substrate into a fluorescent product that can be measured.
 162 At low concentrations of proteins, beads carry either zero or low numbers of enzymes and protein
 163 concentration is quantified by counting the presence of “on” or “off” bead (digital). At higher
 164 concentration of protein, each bead carries multiple enzymes and the total fluorescence signal is
 165 proportional to the amount of protein in the sample (analog). Both the digital and analog
 166 calculations use the unit “average number of enzyme per bead (AEB)”. The concentrations of
 167 protein in the unknown samples are interpolated from the calibrator curves obtained by 4 parameter
 168 logistic regression fitting.

169

Mutation analysis

The mutational statuses of PIK3CA, BRAF and KRAS mutations were investigated in the cancer tissue using droplet digital polymerase chain reaction (ddPCR). The method has been described in detail in CEB Thomsen et al. [14]. The most frequent KRAS and BRAF mutations were investigated (KRAS G12D, G12V and G13D and BRAF V600E). If negative for these mutations, samples were analysed for 14 KRAS mutations in codon 12, 13, 61, 117 and 146 and 9 NRAS mutations in codons 12, 13 and 61. These 27 KRAS and NRAS mutations were selected based on the literature [7;15] and cover mutations found in more than 0.2% of colorectal cancers. All samples were analysed for the four most common PIK3CA mutations (E542K, E545K, H1047R and H1047L). Of the 176 patients used in this study, 58 patients were Wt for all investigated mutations (33%). Patients with BRAF mutations (n=53, 30%), KRAS mutations (n=56, 32%), NRAS mutations (n=4, 2%) and PIK3CA mutations (n=18, 10%). Patients with mutual mutations for PIK3CA and KRAS or BRAF (n=14, 8%). One patient had no mutational data.

Statistical methods

Data were evaluated using NCSS software version 2007 (Kaysville, UT, USA) using the following statistical analyses: Wilcoxon Signed Ranks test, Mann-Whitney U-test, Spearman's ρ , Kaplan-Meier log-rank test. For all analyses, a p-value < 0.05 was considered statistically significant.

Results

Setting up tERK, pERK, tAKT, pAKT, cyclin d and pp70s6k on the Simoa as single-plex assays.

Figure 2 shows the calibrator curves for tERK, pERK, tAKT, pAKT, cyclin d and pp70s6k assays on the Simoa. The concentrations of the calibrators range from 0 to 2000 pg/ml for pAKT, 0 to 3000 pg/ml for cyclin d and 0 to 5000 pg/ml for tAKT, tERK, pERK and pp70s6k. Comparing the Simoa assays with traditional immunoassays an increase in sensitivity from 8-fold to 250-fold was achieved. For each assay, concentrations of the detection antibody and SβG have been optimized together with testing different sample/calibrator diluents to minimize matrix effects. The final parameters used are described in the materials and methods.

Fig 2. pERK, tERK, pAKT, tAKT, pp70s6k and cyclin d calibrator curves using Simoa.

Fig 2. The average number of enzyme per bead (AEB) against concentration is shown. The calibrators (n=8) were run in duplicate and the mean value for each point of the calibrators is shown.

Validating the single-plex assays.

To study the matrix effects in the tissue lysate, samples were diluted in sample diluent ranging between 4 and 256 fold (4, 8, 16, 32, 64, 128, 256). The tissue samples show acceptable linearity between a dilution of 30 and 128 fold in all assays. In order to overcome matrix effects a 30-fold dilution of the samples was used. Limit of detection (LOD) was determined using 3 standard deviations (SD) from the background. Sample diluent was included at least 8 times over several days and the mean LOD was estimated (Table 1). For determining the intra-assay CV%, controls

were analyzed in replicates of at least 6 in one assay and the total CV% was calculated from runs from different days (Table 1).

Table 1. Performance of the assays.

	LOD pg/ml	Control levels pg/ml	Intra-assay CV%	Total CV%
tERK	3.8	110	6	17
		230	10	15
pERK	3.6	40	5	13
		180	8	18
tAKT	10	140	10	23
		490	11	29
pAKT	2.0	10	6	24
		40	7	19
cyclin d	3.2	20	9	24
		80	14	23
pp70s6k	3.8	30	4	19
		150	8	11

Autologous reference tissue and cancer tissue.

tERK, pERK, tAKT, pAKT, cyclin d and pp70s6k were measured in both autologous reference tissue and colon cancer tissue (Fig 3 and Table 2). Both pERK and tERK were found to be down-regulated in cancer tissue ($p= 0.001$) while pAKT, tAKT, cyclin d and pp70s6k showed no differences between the tissues. Testing for variance differences between the tissue groups using Modified-Levene Equal Variance Test showed significant differences ($p< 0.0001$) for tAKT, pAKT, tERK and cyclin d.

225

226 **Table 2. Pathway protein concentrations in autologous reference and cancer tissue.**

	Autologous reference tissue Median (range) pg/ml	Cancer tissue Median (range) pg/ml
tERK	111 (2-349)	75 (0.6-421)
pERK	83 (1-8174)	61 (0.1-391)
tAKT	202 (7-721)	199 (0.4-1674)
pAKT	11 (0.4-46)	8 (0.1-115)
cyclin d	37 (0.2-183)	33 (0.2-470)
pp70s6k	78 (5-480)	93 (16-739)

227 The median and range are shown for each pathway protein.

228

229 **Fig 3. Pathway protein concentrations in cancer tissue and autologous reference tissue.**

230 Fig 3. The horizontal lines demonstrate the median values.

231

232 **Correlations between the pathway proteins.**

233 Associations between the pathway proteins in autologous reference tissue or cancer tissue were
 234 investigated. The Spearman's rank correlation coefficients are shown in Table 3. In the autologous
 235 reference tissue the correlation between tAKT and pp70s6k was statistically significant ($p=0.0003$).
 236 All other cases also showed statistically significant correlations ($p<0.000001$). Furthermore
 237 significant correlations were found between cancer tissue and autologous reference tissue regarding
 238 tAKT ($p=0.003$) and cyclin d ($p=0.03$).

239

240 **Table 3. Correlations between the pathway proteins.**

R values	pERK	tAKT	pAKT	cyclin d	pp70s6k
Cancer tissue					

tERK	0.91	0.80	0.85	0.81	0.50
pERK	-	0.85	0.90	0.86	0.54
tAKT	-	-	0.93	0.81	0.54
pAKT	-	-	-	0.88	0.58
cyclin d	-	-	-	-	0.61
Autologous reference tissue					
tERK	0.93	0.74	0.74	0.69	0.56
pERK	-	0.75	0.76	0.67	0.53
tAKT	-	-	0.78	0.58	0.37
pAKT	-	-	-	0.66	0.53
cyclin d	-	-	-	-	0.77

241 R values were calculated using Spearman's rank.

242

243 **Pathway proteins and mutational status.**

244 The concentrations of tERK, pERK, tAKT, pAKT, cyclin d and pp70s6k in colon cancer tissue
 245 were compared with the mutational statuses Wt, KRAS, BRAF and PIK3CA. The median and range
 246 values for all proteins are shown in Table 4. Patients with a BRAF mutation had significant
 247 decreased concentrations of tERK (p=0.0004), pERK (p=0.0002), tAKT (p=0.0002), pAKT
 248 (p=0.00004) and cyclin d (p=0.001) as compared with Wt (Fig 4). Patients with a PIK3CA mutation
 249 had significant decreased concentrations of tAKT as compared to Wt (p=0.042). There were no
 250 significant differences between patients with a KRAS mutation and Wt patients for either pathway
 251 protein.

252

253 **Table 4. Pathway protein concentrations according to mutation status.**

Cancer tissue Median (range) pg/ml	Wt	KRAS	BRAF	PIK3CA
---------------------------------------	----	------	------	--------

tERK	99 (0.6-407)	108 (0.6-421)	27 (1-356)	54 (4.5-421)
pERK	81 (0.2-298)	85 (0.1-391)	24 (0.2-298)	38 (1.6-391)
tAKT	226 (0.4-1212)	296 (6.5-1253)	79 (0.8-1030)	97 (7.6-1253)
pAKT	10 (0.1-96)	14 (0.1-106)	3.3 (0.2-66)	4.4 (0.2-106)
cyclin d	39 (0.2-211)	49 (0.2-231)	16 (0.2-146)	26 (0.2-209)
pp70s6k	90 (40-352)	110 (31-453)	73 (16-283)	107 (16-371)

The median and range are shown for each pathway protein. Wt is wildtype for all investigated mutations.

Fig 4. Pathway protein concentrations in cancer tissue with BRAF mutations or wt.

Fig 4. The horizontal lines depict the median values.

Clinical data.

For each pathway protein the median concentration value was used as cut off and tested for its ability to distinguish between patients with different prognosis. Also the autologous reference tissue was used to establish cut off values for each pathway protein. There were no significant differences between patients with high concentrations and those with low concentrations using either discrimination cut off regarding disease free survival or overall survival.

Using the cut off values established from the autologous reference tissue and categorizing the cohort according to BRAF mutations a decreased overall survival was observed for patients with high levels of tERK ($p=0.046$), tAKT and pAKT ($p=0.003$) (Fig 5). Moreover patients with BRAF mutations showed decreased disease free survival for pERK ($p=0.03$), tAKT ($p=0.019$) and pAKT ($p=0.034$) (data not shown). Patients with KRAS mutations and low levels of pp70s6k demonstrated decreased overall survival ($p=0.04$) (Fig 5). Furthermore patients with KRAS mutations, stage 2 cancer and low concentrations of pp70s6k ($p=0.003$), cyclin d ($p=0.045$), tAKT ($p=0.03$), pAKT ($p=0.03$), tERK ($p=0.04$) or pERK ($p=0.04$) had inferior overall survival (Fig 6).

274

275 **Fig 5. Overall survival in patients with BRAF or KRAS mutations.**

276 Fig 5. Kaplan-Meier curves. Numbers in parentheses indicate events/total number of patients.

277

278 **Fig 6. Overall survival in patients with stage 2 disease and KRAS mutations.**

279 Fig 6. Kaplan-Meier curves. Numbers in parentheses indicate events/total number of patients.

280

281 Discussion

282 In this study quantitative methods were developed using Simoa technology for measuring AKT,
283 ERK, cyclin d and pp70s6k in localized colon cancer tissue to investigate their correlation to
284 prognosis and their relation to upstream mutations in the pathways.

285 The colon tissues were stored in RNAlater which might be a limitation of the study since the
286 RNAlater solution contains a high level of ammonium sulfates which denature proteins. We
287 therefore ensured that the developed assays were compatible with denatured proteins. Other studies
288 have found that tissue preserved in RNAlater is suitable for ELISA-based methods [16;17].

289 PERK and tERK were found to be significantly down-regulated in cancer tissue as compared with
290 autologous reference tissue which is also in agreement with the literature [18-22]. Furthermore,
291 cancer tissue with a BRAF mutation demonstrated significant lower concentrations of pathway
292 proteins as compared with Wt. We included 53 patients with a BRAF mutation while other studies
293 using CRC patients have less than 12 patients with BRAF mutations included. The limited number
294 of patients in these studies may be the reason for the divergent results they demonstrate [23-25].

295 No statistically significant correlations were found between ERK, AKT, pp70s6k or cyclin d and
296 disease free survival or overall survival in the localized colon cancer patient cohort used in this
297 study. However, stratifying according to mutation status, patients with BRAF mutations and high
298 concentrations of ERK or AKT had low overall survival. Furthermore patients with KRAS
299 mutations and low levels of pp70s6k had decreased overall survival and patients with KRAS
300 mutations, stage 2 cancer and low concentrations of any of the measured pathway proteins
301 demonstrated decreased overall survival. These results are based on a limited number of patients in
302 each group and more patients are needed to document these findings. Studies on AKT or ERK
303 activation have yielded variable results regarding survival. Malinowsky et al. showed that activation
304 of AKT correlated with decreased survival, while Baba et al. showed that AKT activation was

305 associated with a favorable outcome. Schmitz et al. found that the activation of ERK but not AKT
 306 predicted poor prognosis [25-27]. The majority of these studies included both colon- and rectal
 307 tumors and differences in prognostic value in the two groups may be possible. Also method
 308 differences, mutation data, sample sizes are some of the factors that might explain the divergent
 309 results.

310 Cancer tissues with genetic mutations result in a constitutive activation of the intracellular
 311 pathways. It is therefore plausible, that an increased activation and turn-over may lead to an over-
 312 production or consumption of native proteins as seen in the complement and coagulation pathway
 313 cascades. In this study there was an overall statistically significant correlation between pathway
 314 protein concentrations and mutational status. However, the change in pathway protein
 315 concentrations is too small to be used as screening indicators for mutations in practical medical use
 316 and our hypothesis could therefore not be confirmed. As in the complement and coagulation
 317 pathways the correct way to detect an increase in activity is to quantify not the native proteins but
 318 degradation or split products from the single intracellular pathway proteins. Therefore, we now aim
 319 to develop specific antibodies and methods to measure these degradation products, as previously
 320 done for complement C3d [28;29]. We believe this approach will increase both the prediction of
 321 mutations and survival.

322 **Declaration of interest**

323 None

324

325 **Funding**

326 This research was funded by the Region of Southern Denmark as part of the Clinical Center of
327 Excellence in colorectal cancer at Vejle Hospital, Denmark

328

329 **Acknowledgements**

330 The authors thank the laboratory technologists Sara Egsgaard, Camilla Davidsen and Lone Karlsen
331 Jensen, Department of Immunology and Biochemistry, for excellent technical assistance and
332 continuous dedicated work.

333

334

References

1. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev* 2004 Jun;68(2):320-44.
2. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev* 2011 Mar;75(1):50-83.
3. Seger R, Krebs EG. The MAPK signaling cascade. *FASEB J* 1995 Jun;9(9):726-35.
4. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. *Growth Factors* 2006 Mar;24(1):21-44.
5. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007 Jun 29;129(7):1261-74.
6. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. *Genes Dev* 2002 Jun 15;16(12):1472-87.
7. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. *Genes Chromosomes Cancer* 2011 May;50(5):307-12.
8. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. *JAMA Oncol* 2019 May 9.
9. Farina-Sarasqueta A, van LG, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. *Ann Oncol* 2010 Dec;21(12):2396-402.
10. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004 Apr 23;304(5670):554.
11. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012 Jul 18;487(7407):330-7.
12. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, et al. Colorectal cancer: mutations in a signalling pathway. *Nature* 2005 Aug 11;436(7052):792.
13. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 Analyzer: A Novel Fully Automated Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. *J Lab Autom* 2016 Aug;21(4):533-47.

- 367 14. Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. The
368 prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon
369 cancer. *Cancer Med* 2017 May;6(5):928-36.
- 370 15. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-
371 FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013 Sep
372 12;369(11):1023-34.
- 373 16. Blacksell SD, Khounsy S, Westbury HA. The effect of sample degradation and RNA
374 stabilization on classical swine fever virus RT-PCR and ELISA methods. *J Virol Methods*
375 2004 Jun 1;118(1):33-7.
- 376 17. Reiser V, Smith RC, Xue J, Kurtz MM, Liu R, Legrand C, et al. High-throughput
377 simultaneous analysis of RNA, protein, and lipid biomarkers in heterogeneous tissue samples.
378 *Clin Chem* 2011 Nov;57(11):1545-55.
- 379 18. Eggstein S, Franke M, Kutschka I, Manthey G, von Specht BU, Ruf G, et al. Expression and
380 activity of mitogen activated protein kinases in human colorectal carcinoma. *Gut* 1999
381 Jun;44(6):834-8.
- 382 19. Gulmann C, Sheehan KM, Conroy RM, Wulfkühle JD, Espina V, Mullarkey MJ, et al.
383 Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in
384 colorectal cancer. *J Pathol* 2009 Aug;218(4):514-9.
- 385 20. Park KS, Kim NG, Kim JJ, Kim H, Ahn YH, Choi KY. Differential regulation of MAP kinase
386 cascade in human colorectal tumorigenesis. *Br J Cancer* 1999 Dec;81(7):1116-21.
- 387 21. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS/BRAF mutation
388 status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal
389 cancer. *Mol Cancer Ther* 2009 Apr;8(4):834-43.
- 390 22. Wang Q, Ding Q, Dong Z, Ehlers RA, Evers BM. Downregulation of mitogen-activated
391 protein kinases in human colon cancers. *Anticancer Res* 2000 Jan;20(1A):75-83.
- 392 23. Holck S, Bonde J, Pedersen H, Petersen AA, Chaube A, Nielsen HJ, et al. Localization of
393 active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer
394 with or without activating BRAF and KRAS mutations. *Hum Pathol* 2016 Mar 29.
- 395 24. Levidou G, Saetta AA, Gigelou F, Karlou M, Papanastasiou P, Stamatelli A, et al. ERK/pERK
396 expression and B-raf mutations in colon adenocarcinomas: correlation with
397 clinicopathological characteristics. *World J Surg Oncol* 2012;10:47.
- 398 25. Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauder MA, Worm K, et al. Activation of
399 extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal
400 carcinoma and is associated with k-ras mutations. *Virchows Arch* 2007 Feb;450(2):151-9.
- 401 26. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, et al. Phosphorylated
402 AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in
403 717 colorectal cancers. *Cancer* 2011 Apr 1;117(7):1399-408.

27. Malinowsky K, Nitsche U, Janssen KP, Bader FG, Spath C, Drecol E, et al. Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer. Br J Cancer 2014 Apr 15;110(8):2081-9.
28. Brandslund I, Siersted HC, Svehag SE, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods 1981;44(1):63-71.
29. Rasmussen KJ, Skjoedt MO, Vitved L, Skjoedt K, Palarasah Y. A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product. J Immunol Methods 2017 May;444:51-5.

bioRxiv preprint doi: <https://doi.org/10.1101/695809>; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/695809>; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/695809>; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 3

Figure 4

bioRxiv preprint doi: <https://doi.org/10.1101/695809>; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 5

bioRxiv preprint doi: <https://doi.org/10.1101/695809>; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 6